Related Experiment Video
Updated: Nov 16, 2025
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
444
Phospho-eIF4E: A New Target for Acute Myeloid Leukemia.
1College of Life Sciences, China Jiliang University, Hangzhou, 310018, China.
Current Protein & Peptide Science
|February 19, 2021
Summary
Phospho-eIF4E (p-eIF4E) is highly expressed in acute myeloid leukemia (AML), correlating with poor prognosis. Targeting p-eIF4E offers a potential new biological therapy for AML patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Eukaryotic translation initiation factor 4E (eIF4E) dysregulation drives tumorigenesis and cancer progression.
- Phosphorylation of eIF4E at Serine 209 produces phospho-eIF4E (p-eIF4E), a key signaling molecule in cancer-related pathways.
- The nuclear expression and precise molecular mechanisms of p-eIF4E in cancer remain under investigation.
Purpose of the Study:
- To review the role of p-eIF4E as a prognostic indicator in cancer.
- To explore p-eIF4E as a potential therapeutic target for biological therapy in acute myeloid leukemia (AML).
Main Methods:
- Literature review focusing on p-eIF4E expression and function in cancer.
- Analysis of studies investigating p-eIF4E in acute myeloid leukemia (AML).
Main Results:
- p-eIF4E is selectively and highly expressed in AML.
- Elevated p-eIF4E expression in AML is associated with poor patient outcomes and prognosis.
- The role of p-eIF4E in oncogenic transformation is actively researched as a therapeutic target.
Conclusions:
- p-eIF4E serves as a significant prognostic biomarker in AML.
- Targeting p-eIF4E presents a promising strategy for novel biological therapies in AML treatment.
Related Concept Videos
02:38Mitogens and the Cell Cycle
7.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.5K
02:54Protein Kinases and Phosphatases
14.2K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
14.2K
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K